<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02361372</url>
  </required_header>
  <id_info>
    <org_study_id>NSC-99-2324-B-005-017-CC1</org_study_id>
    <nct_id>NCT02361372</nct_id>
  </id_info>
  <brief_title>Kefir on Bone Mineral Density and Bone Metabolism in Osteoporotic Patients</brief_title>
  <official_title>Short-term Effect of Kefir-fermented Milk Consumption on Bone Mineral Density and Bone Metabolism in Osteoporotic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Science and Technology, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ministry of Science and Technology, Taiwan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a controlled, parallel, double-blind intervention study over 6 months, the investigators
      investigated the effects of kefir-fermented milk (1,600 mg/kg) supplemented with calcium
      bicarbonate (CaCO3, 1,500 mg/kg) and bone metabolism in 40 osteoporosis patients, and
      compared them with CaCO3 alone without kefir supplements. Bone turnover markers were measured
      in fasting blood samples collected before therapy and at 1, 3, and 6 months. BMD values at
      the spine, total hip, and hip femoral neck were assessed by dual-energy x-ray absorptiometry
      (DXA) at baseline and at 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bone mineral density and bone regeneration</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Kefir and CaCO3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Kefir were administered 1,600 mg kefir-fermented milk per day and an accompanying supplement of 1,500 mg CaCO3 for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and CaCO3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and 1,500 mg of CaCO3 daily for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo daily for 6 months</description>
    <arm_group_label>Placebo and CaCO3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CaCO3</intervention_name>
    <description>CaCO3 daily for 6 months</description>
    <arm_group_label>Placebo and CaCO3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Kefir</intervention_name>
    <description>Kefir daily for 6 months</description>
    <arm_group_label>Kefir and CaCO3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of osteoporosis patients

        Exclusion Criteria:

          -  Any previous use of parathyroid hormone or sodium fluoride, use of anabolic steroids
             or growth hormone within 6 months before trial entry or oral or intravenous systemic
             corticosteroids within 12 months, and any previous use of strontium.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2014</study_first_submitted>
  <study_first_submitted_qc>February 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2015</study_first_posted>
  <last_update_submitted>August 30, 2015</last_update_submitted>
  <last_update_submitted_qc>August 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ministry of Science and Technology, Taiwan</investigator_affiliation>
    <investigator_full_name>Min-Yu Tu</investigator_full_name>
    <investigator_title>Ministry of Science and Technology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

